AKT1 and benign prostatic hyperplasia: The present study was designed to further explore the antiproliferative effects of avellanin A on RWPE-1 cells, ultimately revealing that this novel candidate therapeutic agent may inhibit PI3K-Akt pathway activity, suggesting that it may be useful as a new option for treating BPH patients.